Vincent J. Picozzi

3 weeks ago | ajmc.com | Pearl Steinzor |Dirk Arnold |Vincent J. Picozzi |Danny Rischin

Oncology professionals reflect on the unique value of attending the American Society of Clinical Oncology (ASCO) annual meeting—from discovering new clinical trial results to reconnecting with peers from around the world. With major practice-changing research and global thought leadership in one place, ASCO continues to be a can't-miss event for the cancer care community.

4 weeks ago | ajmc.com | Pearl Steinzor |Vincent J. Picozzi

The randomized phase 3 trial PANOVA-3 (NCT03377491) demonstrated a significant breakthrough, adding approximately 2 months to overall patient survival in locally advanced pancreatic cancer (LA-PAC), with notable improvements in quality of life and pain progression prevention, explains Vincent Picozzi, MD, medical oncologist and director of the Pancreaticobiliary Program, Virginia Mason. The data were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting.

4 weeks ago | brnw.ch | Vincent J. Picozzi |Javier Gallego |Andrea Bullock

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.